SURVEY AND SUMMARY

New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone

Hsiao P.J. Voon and Lee H. Wong*

Department of Biochemistry and Molecular Biology, The Biomedicine Discovery Institute, Monash University, Wellington Road, Clayton, Victoria 3800, Australia

Received November 09, 2015; Revised December 26, 2015; Accepted December 31, 2015

ABSTRACT

A number of studies have demonstrated that various components of the ATRX/DAXX/Histone H3.3 complex are important for heterochromatin silencing at multiple genomic regions. We provide an overview of the individual components (ATRX, DAXX and/or H3.3) tested in each study and propose a model where the ATRX/DAXX chaperone complex deposits H3.3 to maintain the H3K9me3 modification at heterochromatin throughout the genome.

INTRODUCTION

The DNA in eukaryotic cells is wrapped around histones which can be post-translationally modified to regulate transcription. Large genomes, such as the mouse and human genomes, are replete with repetitive sequences including tandem repeats at centromeres and telomeres, and interspersed repeats (e.g. LINEs, SINEs, Alu repeats and ERVs). In order to prevent aberrant transcription, these genomic repeats are packaged into constitutive heterochromatin, a condensed chromatin structure which restricts accessibility to transcriptional machinery. Aberrant transcription of these repeats can compromise genome integrity and maintaining the heterochromatic architecture at these sites is critical to genome stability (1). The passage of polymerases during DNA replication or transcription poses a threat to chromatin and the timely restoration of nucleosomes is important for maintaining epigenetic memory (2).

The replication of DNA during S-phase is accompanied by the deposition of newly synthesised histones as chromatin is rapidly reassembled behind the replication fork (3). The canonical histones, H3.1/H3.2, are specifically expressed during this period and incorporated into chromatin in a replication-coupled manner. In contrast, the histone variant H3.3 is expressed throughout the cell cycle and deposition of this variant is replication-independent (4–6). In addition to the distinct expression patterns, H3.3 differs from the canonical H3.1/H3.2 counterparts at five amino acid residues. These substitutions in H3.3 mediate interactions with chaperone complexes which are unique to H3.3 (7,8) and facilitate the replication-independent deposition of this variant (4). Two major H3.3-specific chaperones have been identified; the HIRA complex which deposits H3.3 at genic regions (5,6) and the ATRX/DAXX complex which is responsible for H3.3 deposition at repetitive regions of the genome (9–11).

The association of H3.3 with heterochromatin was first reported at the telomeres of mouse ES cells (12). This was closely followed by the identification of a chaperone complex comprised of ATRX and DAXX (9,10). ATRX is a chromatin remodeller which is thought to localise to telomeres via interactions with G-quadruplex secondary structures (13,14) while DAXX is an H3.3-specific chaperone (8). Both components of the ATRX/DAXX complex were found to be essential for the deposition of H3.3 at telomeres (9,10) and pericentric heterochromatin (PCH; 11) though the functional significance of this pathway was unclear. More recent studies have now demonstrated that ATRX/DAXX mediated deposition of H3.3 is not limited to telomeric and pericentric repeats but occurs at heterochromatin distributed throughout the genome of mouse ES cells (15–18), including endogenous retroviral repeats (ERVs; 16–18), imprinted differentially methylated regions (DMRs) and selected intragenic methylated CpG islands (CGIs; 15). ATRX/DAXX/H3.3 enrichment at these sites coincides with the H3K9me3 heterochromatin modification and disruption of ATRX, DAXX or H3.3 led to a loss of H3K9me3 at these regions (15,16,18–20). This review will consolidate the major findings of these studies and outline the evidence to support a model where ATRX/DAXX deposits H3.3 to maintain H3K9me3 heterochromatin in the genome.

*To whom correspondence should be addressed. Tel: +61 3 9902 4925; Fax: +61 3 9902 9500; Email: lee.wong@monash.edu

© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
The ATRX/DAXX complex localises to heterochromatin

The interaction between the ATRX/DAXX complex and histone H3.3 was first described at telomeres and PCH (9–11). These highly repetitive regions of the genome are archetypal constitutive heterochromatin, and well documented as being enriched for H3K9me3, H4K20me3 and DNA methylation. More recent ChIP-seq studies have demonstrated that ATRX binding sites across the genome are generally associated with heterochromatic modifications (H3K9me3, H4K20me3, DNA methylation; 15). Further supporting the idea that ATRX localises to heterochromatin, a number of studies detected ATRX (15–18) and DAXX (16,18) enrichment at ERV repeats, particularly at IAP repeats (Intracisternal A particle; 16,18). ERVs are transposable elements which are known to be modified as silent heterochromatin, as aberrant expression results in genome instability (1). Consistent with this, ATRX/DAXX binding at ERVs coincided with enrichment of H3K9me3 and the co-repressor complex KAP1 (aka Trim28) and SETDB1 (aka ESET; 16,17), a lysine methyltransferase which catalyses H3K9me3. It is likely that the heterochromatin modifications at these regions directly ATRX binding as the ADD domain of ATRX has been demonstrated to specifically recognise H3K9me3 (21–23). This interaction has been confirmed at the cellular level where ATRX localisation to PCH was demonstrated to be dependent on H3K9me3 catalysed by SUV39H (23). Furthermore the monoallelic localisation of ATRX to the methylated, heterochromatic allele of imprinted DMRs (15) demonstrates that chromatin modifications play an important role in directing ATRX localisation.

ATRX/DAXX is required for H3.3 deposition at heterochromatin

The ATRX/DAXX complex is known to be important for deposition of H3.3 at telomeres and PCH. ChIP-seq of endogenous H3.3 in WT, ATRX KO (15,16) and DAXX KO (16) cells demonstrated that this was also true for the methylated allele of imprinted genes (15) as well as certain tandem repeats and intragenic CGIs (15). H3.3 was found to be generally enriched at ATRX binding sites in WT cells and this enrichment was lost in ATRX KO (15,16) and DAXX KO cells (16). H3.3 was also found to be enriched at IAP/ERV retrotransposons (15–17) although there is some disagreement about the requirement of ATRX/DAXX for H3.3 deposition at these sites. Two studies reported that ATRX/DAXX KO results in loss of H3.3 at IAP/ERVs (15,16) while one study reported increased H3.3 at IAP/ERVs in ATRX KO cells (17). The primary difference between these studies is that ChIP was performed either against endogenous H3.3 (15,16) or an YFP-tagged H3.3 (9).

We have eliminated bioinformatics analysis as a possible variable by using a single method to re-align all three data sets. Similar to Sadic et al. (17), when we mapped the YFP-tagged H3.3 data set (9) to IAPEz repeats (Figure 1), we detected a gain of YFP-H3.3 at this ERV in ATRX KO cells. However, the two H3.3 data sets generated using an antibody against endogenous H3.3 (15,16) did not recapitulate this result and H3.3 enrichment at IAPEz ERVs was consistently lost in ATRX KO cells (Figure 1). H3.3 ChIP-seq reads from all three data sets were also mapped to the telomeres as a control. ATRX KO led to decreased H3.3 incorporation at telomeres in all three data sets although telomere enrichment was clearer for endogenous H3.3, compared to the YFP-tagged H3.3, in normal cells (Figure 1). Several lines of evidence appear to support ChIP data sets of endogenous H3.3. The relative enrichment profile of H3.3 at ERVs compared to telomeres in the endogenous H3.3 ChIP data sets are in agreement with immunofluorescence analyses (10,12). In addition, upregulated IAP expression was detected in both ATRX KO (17) and H3.3 KO cells (16; see below), supporting a role for ATRX/DAXX-dependent deposition of H3.3 at ERVs, in agreement with the endogenous H3.3 ChIP-seq data.

It is possible that the discrepancy between the endogenous H3.3 and YFP-H3.3 has arisen due to the introduction of the YFP tag. For example, H3.3 turnover has been demonstrated to be important for regulation (24) and the YFP tag may interfere with this process. However, it is clear that further experiments are required to reconcile the discrepancies between these data sets. Future analysis using a different epitope tag, a different antibody or H3.3 K9 mutant cells would be useful for clarifying the differences between these studies. Nonetheless, when taken together, these results suggest that ATRX/DAXX localises to selected heterochromatic regions in the genome and deposits H3.3. This pathway has now been extended from telomeres and PCH to also include methylated imprinted DMRs, ERVs/IAPs and selected short tandem repeats.

ATRX/DAXX mediated deposition of H3.3 is required for maintaining H3K9me3

In addition to the loss of H3.3, disruption of the ATRX/DAXX complex in mouse ES cells also led to the loss of H3K9me3 at some genomic regions. ATRX KO led to a reduction in H3K9me3 at methylated imprinted DMRs, intragenic CGIs (15) and IAP repeats (16) as detected by ChIP-qPCR and ChIP-seq. Similarly, a reduction in H3K9me3 was also detected at IAPs (16) and telomeres (18) in DAXX KO cells. In addition, direct knock-out of H3.3 also led to decreased H3K9me3 at IAPs (16) and telomeres (19,20). ChIP-reChIP assays of H3.3 and H3K9me3 on a genome-wide basis (16) and specifically at telomeres (19) demonstrated that H3.3 at these heterochromatic sites were directly modified with K9me3 (H3K9me3). Overall, these data support a model where ATRX/DAXX mediates deposition of H3.3 which can be modified with K9me3 to facilitate the maintenance of heterochromatin.

SUV39H and SETDB1 catalyse K9me3 on H3.3

The H3K9me3 modification is catalysed by SUV39H1/2 at telomeres and PCH (25,26) while SETDB1 acts in a complex with KAP1 to catalyse H3K9me3 at ERVs (27,28) and methylated imprinted DMRs (29). The KAP1/SETDB1 complex was found to co-localise with ATRX at ERVs (17) and generally with ATRX/DAXX/H3.3/H3K9me3 across
the genome (16). Consistent with previous studies, deple-
tion of SETDB1 led to reduced H3K9me3 at IAPs/ERVs
(16,17) and also at telomeres (19), albeit to a lesser de-
gree. A direct interaction between DAXX and KAP1 has
been identified by co-immunoprecipitation (16) and sug-
gests that DAXX contributes to KAP1 binding at some
genomic sites. Although KRAB-ZNFs, such as ZFP809
at ERVs (30) and ZFP57 at imprinted genes (29,31), are
known to be the main determinant for KAP1 localisa-
tion, it is possible that DAXX may help to further stabilise
these interactions. Overall, these studies suggest that the
KAP1/SETDB1 complex is able to catalyse H3.3K9me3 at
these sites. In addition, DAXX (18) and H3.3 (19) were
also found to interact with SUV39H and depletion of SUV39H
led to a loss in H3.3 K9me3 at telomeres (19). Combined,
these results demonstrate that both SETDB1 and SUV39H
are able to catalyse the trimethylation of lysine 9 on H3.3.

**Disruption of ATRX/DAXX/H3.3K9me3 leads to aberrant transcription**

Previous studies have shown that ATRX KO leads to in-
creased TERRA transcription at telomeres (9) and this
was verified by siRNA depletion of ATRX and DAXX
(18). Knockout of histone H3.3 similarly led to in-
creased TERRA transcription (19) confirming that the
ATRX/DAXX deposition of H3.3 is important for sup-
pressing telomere transcription. This has now been ex-
tended to other genomic loci; ATRX KO cells failed to si-
lence a mini-IAP transgene (17) and resulted in aberrant
allelic expression of imprinted genes (15) while H3.3 KO
led to increased ERV transcription in mouse ES cells (16).
It should be noted that multiple mechanisms may mediate
transcriptional silencing at these genomic regions and the
ATRX/DAXX/H3.3 complex is one of many heterochro-
matin factors which maintain silencing. The degree of tran-
scriptional deregulation varies depending on which hete-
rochromatin pathway is disrupted, however, aberrant tran-
scription is a reliable indicator of alterations in the under-
lying chromatin structure. The importance of ATRX/H3.3
in heterochromatin maintenance is further demonstrated
by the decrease in other silent chromatin modifications in-
cluding H4K20me3 at telomeres (19) and DNA methyl-
ation at DMRs of imprinted genes (15). Taken together, these
studies demonstrate that ATRX/DAXX deposition of H3.3
K9me3 is important for maintaining silent heterochromatin
at a number of genomic sites.

**CONCLUSIONS**

A substantial proportion of mammalian genomes is com-
prised of repetitive DNA which includes telomeres, cen-
tromeres and ERVs. Aberrant transcription of these repeats
is deleterious to the organism and maintaining heterochro-
matic silencing at these repeats is critical for protecting ge-
nomic integrity. Chromatin modifications, such as DNA
methylation, H3K9me3 and H4K20me3, are known to be
important for maintaining silencing. In addition, a recent
set of studies have now also identified the histone vari-
ant H3.3 as an important component of heterochromatin
in mouse ES cells. The complex which deposits H3.3 at
heterochromatin is comprised of DAXX, an H3.3 specific
chaperone, and a chromatin remodeler, ATRX. This chape-
ron complex both targets H3.3 to specific heterochro-
matic sites and interacts with histone modifiers to main-
tain the K9me3 heterochromatin mark. The ADD domain
of ATRX preferentially interacts with H3K9me3 which
likely drives the localisation of ATRX/DAXX/H3.3 to het-
erochromatin modified regions including telomeres, ERVs
and the methylated imprinted DMRs. DAXX is then able

1. GSE16893 (Goldberg et al. [9], Sadic et al. [17])
2. GSE59270 (Voorn et al. [15])
3. GSE59189 (Elssasser et al. [16])

Figure 1. Raw read files of YFP-H3.3 ChIP (9), endogenous H3.3 ChIP (15,16) and matched input sequencing from WT and ATRX KO cells were
downloaded from GEO (35,36) and mapped to repeats with Repeat Enrichment Estimator (37). Samples were normalised for total read counts by dividing
mapped reads against total mappable reads. Results show normalised reads counts of H3.3 ChIP and matched input samples for each dataset at (A) IAPEz
repeats and (B) telomere repeats. YFP-H3.3 was increased at IAPEz repeats in ATRX KO relative to WT cells. Endogenous H3.3 was decreased at IAPEz
repeats in ATRX KO relative to WT cells. All three data sets showed decreased H3.3/YFP-H3.3 at telomeres in ATRX KO relative to WT cells.
Figure 2. Model for ATRX/DAXX/H3.3 in maintaining heterochromatin. (A) Heterochromatic regions such as telomeres, IAP LTRs and methylated imprinted DMRs are distributed throughout the genome and enriched for H3K9me3. (B) ATRX recognises H3K9me3 and acts with DAXX to deposit H3.3 to replace histones which are lost. DAXX interacts with KAP1 and SETDB1 to catalyse K9me3 on newly deposited H3.3. ATRX/DAXX/H3.3 are able to act continuously through the cell cycle to ensure constant maintenance of H3K9me3 heterochromatin.

to interact with either the KAP1/SETDB1 co-repressor complex or SUV39H, both of which catalyse H3K9me3. ATRX/DAXX is therefore able to target heterochromatin for deposition of H3.3 and recruit methyltransferases to mediate direct modification of K9me3 on H3.3. This represents a self-reinforcing pathway which is able to protect heterochromatin integrity throughout the cell cycle (Figure 2).

These studies have identified the ATRX/DAXX/H3.3 complex as an important contributor to heterochromatin silencing in mouse ES cells however, a number of outstanding questions remain. Perhaps the most puzzling of these is why H3.3 is required at all. One possible clue could lie in the replication-independent expression and incorporation of the H3.3 variant. This would suggest that ATRX/DAXX/H3.3 are particularly important outside of S-phase when the canonical histones are unavailable. Future analyses with highly quantitative time-lapse imaging experiments would provide useful information of the dynamics of H3.3, including turnover and deposition of newly synthesised H3.3, and recruitment of other chromatin repressors at these sites. Furthermore, while it is evident that depletion of ATRX/DAXX/H3.3 leads to loss of heterochromatin, the overall phenotypic consequences remain unclear. This is particularly pertinent to ALT cancers where ATRX mutations have been strongly linked to increased recombination at telomeres (32,33). Several studies have demonstrated that disruption of heterochromatin facilitates aberrant telomere recombination (34). Detailed analyses of how heterochromatin structure, including H4K20me3 and DNA methylation, is disrupted in ATRX/DAXX/H3.3 deficient cells would provide insights into how this pathway might promote genome instability in cancer.

ACKNOWLEDGEMENT
The authors wish to thank Joey Man for drawing Figure 2.

FUNDING
Australia Research Council (ARC) Future Fellowship Award from the ARC, Australia [to L.H.W]. Fund-
Protects Tandem Repetitive Elements during DNA Hypomethylation by Promoting H3K9 Trimethylation. Cell Stem Cell, 17, 273–286.
19. Udugama, M., Chang, F.T., Chan, F.L., Tang, M.C., Pickett, H.A., McGhie, J.D., Mayne, L., Collas, P., Mann, J.R. and Wong, L.H. (2015) Histone variant H3.3 provides the heterochromatic H3 lysine 9 tri-methylation mark at telomeres. Nucleic Acids Res., 43, 10227–10237.
20. Jang, C.W., Shibata, Y., Starmmer, J., Yee, D. and Magnuson, T. (2015) Histone H3.3 maintains genome integrity during mammalian development. Genes Dev., 29, 1377–1392.
21. Dhayalan, A., Tamas, R., Bock, I., Tattermusch, A., Dimitrova, E., Kudithipudi, S., Ragozin, S. and Jeltsch, A. (2011) The ATRX-ADD domain links H3 to tail peptides and reads the combined methylation state of K4 and K9. Hum. Mol. Genet., 20, 2195–2203.
22. Eustermann, S., Yang, J.C., Law, M.J., Amos, R., Chapman, L.M., Jelinska, C., Garrick, D., Clynies, D., Gibbons, R.J., Rhodes, D. et al. (2011) Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin. Nat. Struct. Mol. Biol., 18, 777–782.
23. Iwase, S., Xiang, B., Gosh, S., Ram, R., Lewis, P.W., Cochrane, J.C., Allis, C.D., Picketts, D.J., Patel, D.J., Li, H. et al. (2011) ATRX ADD domain links an atypic histone methylation recognition mechanism to human mental-retardation syndrome. Nat. Struct. Mol. Biol., 18, 769–776.
24. Mazei, I., Wenderski, W., Noh, K.M., Bagot, R.C., Tzavaras, N., Purushothaman, I., Elsasser, S.J., Guo, Y., Ionenet, C., Hurd, Y.L. et al. (2015) Critical Role of Histone Turnover in Neuronal Transcription and Plasticity. Neuron, 87, 77–94.
25. Benetti, R., Gonzalez, S., Jiao, C., Schottha, B., Klatt, P., Jenuwien, T. and Blasco, M.A. (2007) SuV4–20h deficiency results in telomere elongation and derepression of telomere recombination. J. Cell Biol., 178, 925–936.
26. Peters, A.H., O’Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Henikoff, S., Weipoltshammer, K., Papagiannis, D., Lacher, M., Kohlimairer, A. et al. (2001) Loss of the Suv39h histone methyltransferases impair mammalian heterochromatin and genome stability. Cell, 107, 323–337.
27. Karimi, M.M., Goyal, P., Maksakova, I.A., Birnley, M., Leung, D., Jiang, X., Shinaka, Y., Mager, D.L., Jones, S., Hirst, M. et al. (2011) DNA methylation and SETDB1/H3K9me3 regulate predominantly distinct sets of genes, retroelements, and chimeric transcripts in mESCs. Stem Cell, 8, 676–687.
28. Leung, D., Du, T., Wagner, U., Xie, W., Lee, A.Y., Goyal, P., Yip, Y., Schofer, C., Weipoltshammer, K., Papagiannis, D., Lacher, M., Kohlimairer, A. et al. (2001) Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell, 107, 323–337.
29. Quenneville, S., Zweig, R., Nagar, S., Akopyan, A., Kapopoulou, A., Jakobsson, J., Offer, N., Backer, I., Pedone, P., Grimaldi, G., Riccio, A. et al. (2011) In embryonic stem cells, ZFP57/KAP1 recognizes a methylated hexanucleotide to affect chromatin and DNA methylation of imprinting control regions. Mol. Cell, 44, 361–372.
30. Wolf, G., Yang, P., Fuchthauer, A.C., Fuchthauer, E.M., Silva, A.M., Park, C., Wu, W., Nielsen, A.L., Pedersen, F.S. and MacFarlan, T.S. (2011) The KRAB zinc finger protein ZFP809 is required to initiate epigenetic silencing of endogenous retroviruses. Genes Dev., 25, 538–554.
31. Zuo, X., Sheng, J., Lai, H.T., McDonald, C.M., Andrade, M., Cullen, D., Bell, F.T., Iacovino, M., Kyba, M., Xu, G. et al. (2012) Zinc finger protein ZFP57 requires its co-factor to recruit DNA methyltransferases and maintains DNA methylation imprint in embryonic stem cells via its transcriptional repression domain. J. Biol. Chem., 287, 2107–2118.
32. Heaphy, C.M., de Wilde, R.F., Jiao, Y., Klein, A.P., Edil, B.H., Shi, C., Bettegowda, C., Rodriguez, F.J., Eberhart, G.C., Hebb, S. et al. (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science, 333, 425.
34. Conomos, D., Pickett, H. A. and Reddel, R. R. (2013) Alternative lengthening of telomeres: remodeling the telomere architecture. *Front. Oncol.*, **3**, 27.

35. Edgar, R., Domrachev, M. and Lash, A. E. (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.*, **30**, 207–210.

36. Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M. et al. (2013) NCBI GEO: archive for functional genomics data sets–update. *Nucleic Acids Res.*, **41**, D991–D995.

37. Day, D. S., Luquette, L. J., Park, P. J. and Kharchenko, P. V. (2010) Estimating enrichment of repetitive elements from high-throughput sequence data. *Genome Biol.*, **11**, R69.